NEWS & INSIGHTS
LATEST NEWS
Femarelle® official launch in Singapore
24 October 2024, official launch of the Femarelle® line – Rejuvenate, Recharge, and Unstoppable – with Professor Andrea Genazzani and Dr June Tan Sheren. The Femarelle® line uses the proprietary ingredient DT56a, which works in the body in a selective manner, supporting the management of symptoms associated with hormonal changes across the different stages of a woman’s life, from peri-menopause to post-menopause. Femarelle® provides a unique non-hormonal botanical solution, that supports healthy female hormonal and mood balance, improves energy levels, and overall quality of life.
Bonjesta® official launch in Singapore
29 July 2024, official launch of Bonjesta®, with Dr Jason Lim, Professor Yariv Yogev, and A/Prof Tan Thiam Chye. Bonjesta® multilayer, extended-release tablets are designed to provide immediate and continuous relief of morning sickness symptoms throughout the day and night. The simple schedule of administration reduces pill burden and improves patient compliance.
UITC launches Anscare™ Scar Reduction Silicone Gel C+
10 January 2024, UITC launches BenQ Anscare Scar Reduction Silicone Gel C+, an advanced silicone gel formula with Vitamin C that softens and flattens both existing and new scars, like keloids and hypertrophic scars that result from surgery injury, C-section, burns, cuts, scrapes, acnes, insect bites. Available at doctors’ clinics.
UITC expands Bioflor® range with Bioflor® capsules
4 November 2023, in addition to Bioflor® sachets, UITC has also launched Bioflor® capsules, which is a more convenient dosage form for adults. Bioflor Saccharomyces boulardii CNCM I-745® is a unique yeast based probiotic drug that is paired together with antibiotics, used for the treatment and prevention of antibiotic-associated diarrhoea.
Bonjesta® regulatory approval by HSA
18 September 2023, UITC is pleased to announce regulatory approval has been obtained for Bonjesta®. Bonjesta® is a faster acting, longer lasting, optimized reformulation of Diclectin®, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.